Effective Anti-tumor Response by TIGIT Blockade Associated With FcγR Engagement and Myeloid Cell Activation
The molecule “T cell immunoreceptor with immunoglobulin and ITIM domain,” or TIGIT, has recently received much attention as a promising target in the treatment of various malignancies. In spite of the quick progression of anti-TIGIT antibodies into clinical testing both as monotherapy and in combina...
| Κύριοι συγγραφείς: | , , , , , , , , , , , |
|---|---|
| Μορφή: | Άρθρο |
| Γλώσσα: | English |
| Έκδοση: |
Frontiers Media S.A.
2020-10-01
|
| Σειρά: | Frontiers in Immunology |
| Θέματα: | |
| Διαθέσιμο Online: | https://www.frontiersin.org/article/10.3389/fimmu.2020.573405/full |